Value Microcaps Zip Code Changers

[Guy]

ADMP – bought @6.3. With a market cap of under $70 million, this biopharmaceutical company has a lot of potential.

Lots of institutional holders and buying lately(13G filings):
ESES holdings 1,741,973 shares
CRT Capital 513,628 shares
GEMINI Fund 375,130 shares
MARXE AUSTIN 525,000 shares

Key Catalysts in Calendar 2014 (from a CRT capital report):

• In Q1 2014, Adamis plans on filing its epinephrine pre-filled syringe to the FDA via the 505(b)(2) pathway. The Company expects to hear back on an approval decision by late 2014/early 2015. Adamis is partnered with Catalent, who is the contract manufacturer.

• By mid-2014, Adamis plans to conduct a small, 80-patient study with its Taper Dry owder Inhaler (DPI) for treatment of COPD/asthma. We believe the main purpose of this trial will be to demonstrate the comparable efficacy profile of its recently acquired inhaler vs. GSK’s Advair (the “gold standard” product in the market). We believe this trial could be completed by Q4’14. Adamis will be supplied the product by 3M.

• By mid’14, we believe Adamis will look to meet with the FDA to discuss its development plans on APC-1000 (beclomethasone inhaler - comparable to TEVA’s QVAR). We believe Adamis has plans to run a Phase 3 study evaluating the efficacy of its product vs. Qvar. On this product, Adamis is partnered with Beximco.

• By late 2014, we believe Adamis could secure additional partners for its Taper Dry Powder Inhaler for international markets. We would not rule out Adamis also looking for potential partners for its APC-1000 beclomethasone product.

Link to the CRT capital research report:

https://docs.google.com/file/d/0Bwgu6jYVrAKiZDVfRWpPZ2E4b0hOc2p0LUZ5MlA4OFFxM0xj/edit?pli=1